Current approaches of tumor immunotherapy

Buzás Krisztián; Kiss Antal; Vizler Csaba: Current approaches of tumor immunotherapy. In: Acta biologica Szegediensis, (59). pp. 69-82. (2015)

[thumbnail of 5969.pdf]
Előnézet
Cikk, tanulmány, mű
5969.pdf

Letöltés (863kB) | Előnézet

Absztrakt (kivonat)

Our immune system, fine-tuned by a long evolution, has a near-infinite capacity to recognize potential pathogens and mutant self proteins. It has also got a varied arsenal of killing mechanisms to battle intruders and mutant cells. Since malignant transformation involves 1) mutations of proteins of various classes and 2) over-expression of non-altered genes, either related or unrelated to the oncogenic process, the adaptive immune system has the potential to recognize and clear malignantly transformed cells. Immunotherapeutic interventions might 1) trigger an immune response to otherwise tolerated tumor antigens, 2) enhance the existing, but insufficient anti-tumor immune response, add new receptors, recombinant antibodies or T cell receptors, to the system, or 4) rely on the transfer of ex vivo expanded immune effector cells. Although tumor immunotherapy is decades-old, immune checkpoint inhibitor therapy, probably the most significant breakthrough, is a development of the last few years. Reaching its maturity, tumor immunotherapy is just now becoming an integral part of tumor therapy.

Mű típusa: Cikk, tanulmány, mű
Rovatcím: Reviews
Befoglaló folyóirat/kiadvány címe: Acta biologica Szegediensis
Dátum: 2015
Kötet: 59
ISSN: 1588-385X
Oldalak: pp. 69-82
Nyelv: angol
Kulcsszavak: Immunológia rákbetegség
Megjegyzések: Bibliogr.: p. 79-82.
Feltöltés dátuma: 2016. okt. 17. 10:36
Utolsó módosítás: 2018. máj. 25. 11:41
URI: http://acta.bibl.u-szeged.hu/id/eprint/36062
Bővebben:
Tétel nézet Tétel nézet